+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CRISPR And Cas Genes Market Size, Share & Trends Analysis Report By Product & Service, By Application (Biomedical, Agricultural), By End-use (Biotechnology & Pharmaceutical Companies), By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 160 Pages
  • May 2023
  • Region: Global
  • Grand View Research
  • ID: 4076528
Description Jump to:
The global CRISPR and Cas genes market size is expected to reach USD 9.61 billion by 2030, growing at a CAGR of 17.15% from 2023 to 2030.The market is expected to register a CAGR of 17.9% during the forecast period, owing to the increasing usage of CRISPR and Cas genes systems in the biomedical research field. The use of CRISPR-Cas systems in diagnostics and the assessment of evolutionary analysis in prokaryotes has significantly increased, owing to the developments in the field of genome editing. The application of this technology enables easy and cost-efficient editing of genes. Genome editing has made a significant advancement in biomedical research, with the present trend of cutting-edge techniques paving the way for the future treatment of different genetic and non-genetic disorders.

The development and implementation of more effective ways for gene targeting and the generation of gene-edited avian species have been facilitated by the availability of the CRISPR/Cas9-mediated gene and genome editing technology. According to an article published on Frontiers in February 2021, CRISPR/Cas9 has become a robust and important tool for gene editing in the poultry industry. Potential applications in several fields would further boost the demand for this technology. The COVID-19 outbreak shifted the researcher’s emphasis to the development of COVID-19 molecular diagnostic tools based on this technology. For instance, in March 2021, Nanyang Technological University researchers in Singapore created a COVID-19 test based on CRISPR that provides results in 30 minutes.

Even after the virus has mutated, this test still discovers it. This would further encourage the other key players to leverage this technique, thereby driving the industry's growth. This technology is increasingly being used for several medical and other applications. Competition over patents for such a gene-editing technology is expected to grow, as more academic institutions and biotech companies attempt to develop new commercial applications of this technology. In addition, there is a lot of potential for this technique to advance with the use of machine learning technologies. For instance, in August 2022, Synthego launched engineered cell libraries, a cutting-edge service that expands access to CRISPR by giving arrayed CRISPR-edited cells for use directly in functional screening experiments.

It has potential applications in disease research. Key players offer tools and solutions for each step of the gene editing workflow. Integrating several tools, services, and improved processes makes it possible to complete research experiments rapidly and with little effort. Moreover, key players have raised significant funding to support the R&D of the CRISPR & Cas9 gene-editing approach. For instance, in April 2021, Vertex Pharmaceuticals collaborated with CRISPR Therapeutics to develop and manufacture a new CRISPR/Cas9-based gene editing therapy called CTX001, a potential therapeutic option for transfusion-dependent beta-thalassemia and Sickle Cell Disease (SCD). In January 2020, Mammoth Biosciences raised USD 45 million to develop next-gen CRISPR products for therapeutics & diagnostics purposes. This would further be used to develop the company’s CRISPR genes-driven diagnostics portfolio.

CRISPR And Cas Genes Market Report Highlights

  • By product and services, the product segment dominated the industry in 2022 and accounted for the highest share of 78.86%
  • The biomedical segment dominated the industry in 2022. Extensive research and a significant rise in the number of research studies utilizing the advanced technique for genome editing have contributed to the segment growth
  • The biotechnology and pharmaceutical companies dominated the market in 2022, accounting for 49.68% of overall revenue share. Key players are adopting this technology to produce biological models for human diseases and further accelerate new therapeutic target identification
  • North America dominated the market and accounted for the highest revenue share of 38.37% in 2022 owing to the presence of several pharmaceutical giants, increased research funding, a high number of research approvals, and the need for novel therapeutics

Table of Contents

Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information Or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing Need For Novel Therapeutics
3.2.1.2. Rising Demand For Gene Editing
3.2.1.3. Rising Incidence Of Cancer
3.2.2. Market Restraint Analysis
3.2.2.1. Off Target Effects Of CRSIPR Technology
3.2.2.2. High Cost Factor, Intellectual Property Disputes & Ethical Dilemma
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Product & Service Business Analysis
4.1. CRISPR And Cas Genes Market: Product & Service Movement Analysis
4.2. Product
4.2.1. Product Market, 2018 - 2030 (USD Million)
4.2.2. Kits & Enzymes
4.2.2.1. Kits & Enzymes Market, 2018 - 2030 (USD Million)
4.2.2.2. Vector-based Cas9
4.2.2.2.1. Vector-based Cas9 Market, 2018 - 2030 (USD Million)
4.2.2.3. DNA-free Cas9
4.2.2.3.1. DNA-free Cas9 Market, 2018 - 2030 (USD Million)
4.2.3. Libraries
4.2.3.1. Libraries Market, 2018 - 2030 (USD Million)
4.2.4. Design Tool
4.2.4.1. Design Tool Market, 2018 - 2030 (USD Million)
4.2.5. Antibodies
4.2.5.1. Antibodies Market, 2018 - 2030 (USD Million)
4.2.6. Others
4.2.6.1. Other Products Market, 2018 - 2030 (USD Million)
4.3. Service
4.3.1. Service Market, 2018 - 2030 (USD Million)
4.3.2. Cell Line Engineering
4.3.2.1. Cell Line Engineering Market, 2018 - 2030 (USD Million)
4.3.3. gRNA Design
4.3.3.1. gRNA Design Market, 2018 - 2030 (USD Million)
4.3.4. Microbial Gene Editing
4.3.4.1. Microbial Gene Editing Market, 2018 - 2030 (USD Million)
4.3.5. DNA Synthesis
4.3.5.1. DNA synthesis Market, 2018 - 2030 (USD Million)
Chapter 5. Application Business Analysis
5.1. CRISPR And Cas Genes Market: Application Movement Analysis
5.2. Biomedical
5.2.1. Biomedical Market, 2018 - 2030 (USD Million)
5.2.2. Genome Engineering
5.2.2.1. Genome Engineering Market, 2018 - 2030 (USD Million)
5.2.3. Disease Model Studies
5.2.3.1. Disease Model Studies Market, 2018 - 2030 (USD Million)
5.2.4. Functional Genomics
5.2.4.1. Functional Genomics Market, 2018 - 2030 (USD Million)
5.2.5. Epigenetics
5.2.5.1. Epigenetics Market, 2018 - 2030 (USD Million)
5.2.6. Others
5.2.6.1. Other Biomedical Applications Market, 2018 - 2030 (USD Million)
5.3. Agricultural
5.3.1. Agricultural Market, 2018 - 2030 (USD Million)
Chapter 6. End-use Business Analysis
6.1. CRISPR And Cas Genes Market: End-use Movement Analysis
6.2. Biotechnology & Pharmaceutical Companies
6.2.1. Biotechnology & Pharmaceutical Companies Market, 2018 - 2030 (USD Million)
6.3. Academic & Government Research Institutes
6.3.1. Academic & Government Research Institutes Market, 2018 - 2030 (USD Million)
6.4. Contract Research Organizations (CROs)
6.4.1. Contract Research Organizations (CROs) Market, 2018 - 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. CRISPR And Cas Genes Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. SWOT Analysis
7.2.2. North America CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.2.3. U.S.
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Competitive Scenario
7.2.3.4. Regulatory Framework
7.2.3.5. U.S. CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.2.4. Canada
7.2.4.1. Key Country Dynamics
7.2.4.2. Target Disease Prevalence
7.2.4.3. Competitive Scenario
7.2.4.4. Regulatory Framework
7.2.4.5. Canada CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. SWOT Analysis
7.3.2. Europe CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.3.3. UK
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. UK CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.3.4. Germany
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. Germany CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.3.5. France
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Competitive Scenario
7.3.5.4. Regulatory Framework
7.3.5.5. France CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.3.6. Italy
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Competitive Scenario
7.3.6.4. Regulatory Framework
7.3.6.5. Italy CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.3.7. Spain
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Competitive Scenario
7.3.7.4. Regulatory Framework
7.3.7.5. Spain CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.3.8. Denmark
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Competitive Scenario
7.3.8.4. Regulatory Framework
7.3.8.5. Denmark CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.3.9. Sweden
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Competitive Scenario
7.3.9.4. Regulatory Framework
7.3.9.5. Sweden CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.3.10. Norway
7.3.10.1. Key Country Dynamics
7.3.10.2. Target Disease Prevalence
7.3.10.3. Competitive Scenario
7.3.10.4. Regulatory Framework
7.3.10.5. Norway CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. SWOT Analysis
7.4.2. Asia Pacific CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. Japan CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.4.4. China
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. China CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.4.5. India
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. India CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Australia CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. Thailand CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.4.8. South Korea
7.4.8.1. Key Country Dynamics
7.4.8.2. Target Disease Prevalence
7.4.8.3. Competitive Scenario
7.4.8.4. Regulatory Framework
7.4.8.5. South Korea CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. SWOT Analysis
7.5.2. Latin America CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.5.3. Brazil
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Competitive Scenario
7.5.3.4. Regulatory Framework
7.5.3.5. Brazil CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.5.4. Mexico
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Competitive Scenario
7.5.4.4. Regulatory Framework
7.5.4.5. Mexico CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.5.5. Argentina
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Competitive Scenario
7.5.5.4. Regulatory Framework
7.5.5.5. Argentina CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.6. MEA
7.6.1. SWOT Analysis
7.6.2. MEA CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.6.3. South Africa
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Competitive Scenario
7.6.3.4. Regulatory Framework
7.6.3.5. South Africa CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.6.4. Saudi Arabia
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Competitive Scenario
7.6.4.4. Regulatory Framework
7.6.4.5. Saudi Arabia CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.6.5. UAE
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Competitive Scenario
7.6.5.4. Regulatory Framework
7.6.5.5. UAE CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
7.6.6. Kuwait
7.6.6.1. Key Country Dynamics
7.6.6.2. Target Disease Prevalence
7.6.6.3. Competitive Scenario
7.6.6.4. Regulatory Framework
7.6.6.5. Kuwait CRISPR And Cas Genes Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2022
8.4. Company Profiles/Listing
8.4.1. AstraZeneca plc
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Addgene
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Cellectis
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. CRISPR Therapeutics
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Editas Medicine, Inc.
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. eGenesis
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. F. Hoffmann-La Roche Ltd.
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Horizon Discovery Group plc
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Editas Medicine, Inc.
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. GenScript
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
8.4.11. Danaher
8.4.11.1. Overview
8.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.11.3. Product Benchmarking
8.4.11.4. Strategic Initiatives
8.4.12. Intellia Therapeutics, Inc.
8.4.12.1. Overview
8.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.12.3. Product Benchmarking
8.4.12.4. Strategic Initiatives
8.4.13. Merck KGaA
8.4.13.1. Overview
8.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.13.3. Product Benchmarking
8.4.13.4. Strategic Initiatives
8.4.14. Lonza
8.4.14.1. Overview
8.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.14.3. Product Benchmarking
8.4.14.4. Strategic Initiatives
8.4.15. Takara Bio Inc.
8.4.15.1. Overview
8.4.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.15.3. Product Benchmarking
8.4.15.4. Strategic Initiatives
8.4.16. Thermo Fisher Scientific, Inc.
8.4.16.1. Overview
8.4.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.16.3. Product Benchmarking
8.4.16.4. Strategic Initiatives
8.4.17. Synthego
8.4.17.1. Overview
8.4.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.17.3. Product Benchmarking
8.4.17.4. Strategic Initiatives
8.4.18. Mammoth Biosciences
8.4.18.1. Overview
8.4.18.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.18.3. Product Benchmarking
8.4.18.4. Strategic Initiatives
8.4.19. Inscripta, Inc.
8.4.19.1. Overview
8.4.19.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.19.3. Product Benchmarking
8.4.19.4. Strategic Initiatives
8.4.20. Cibus
8.4.20.1. Overview
8.4.20.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.20.3. Product Benchmarking
8.4.20.4. Strategic Initiatives
8.4.21. Beam Therapeutics
8.4.21.1. Overview
8.4.21.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.21.3. Product Benchmarking
8.4.21.4. Strategic Initiatives
8.4.22. PLANTeDIT
8.4.22.1. Overview
8.4.22.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.22.3. Product Benchmarking
8.4.22.4. Strategic Initiatives
8.4.23. Vertex Pharmaceuticals Inc.
8.4.23.1. Overview
8.4.23.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.23.3. Product Benchmarking
8.4.23.4. Strategic Initiatives
8.4.24. Hera BioLabs
8.4.24.1. Overview
8.4.24.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.24.3. Product Benchmarking
8.4.24.4. Strategic Initiatives
8.4.25. OriGene Technologies, Inc.
8.4.25.1. Overview
8.4.25.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.25.3. Product Benchmarking
8.4.25.4. Strategic Initiatives
8.4.26. Recombinetics, Inc.
8.4.26.1. Overview
8.4.26.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.26.3. Product Benchmarking
8.4.26.4. Strategic Initiatives
List of Tables
Table 1 List of abbreviations
Table 2 Global CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 3 Global CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 4 Global CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 5 Global CRISPR and Cas genes market, by region, 2018 - 2030 (USD Million)
Table 6 North America CRISPR and Cas genes market, by country, 2018 - 2030 (USD Million)
Table 7 North America CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 8 North America CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 9 North America CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 10 U.S. CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 11 U.S. CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 12 U.S. CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 13 Canada CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 14 Canada CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 15 Canada CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 16 Europe CRISPR and Cas genes market, by country, 2018 - 2030 (USD Million)
Table 17 Europe CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 18 Europe CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 19 Europe CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 20 Germany CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 21 Germany CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 22 Germany CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 23 UK CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 24 UK CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 25 UK CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 26 France CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 27 France CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 28 France CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 29 Italy CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 30 Italy CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 31 Italy CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 32 Spain CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 33 Spain CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 34 Spain CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 35 Denmark CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 36 Denmark CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 37 Denmark CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 38 Sweden CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 39 Sweden CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 40 Sweden CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 41 Norway CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 42 Norway CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 43 Norway CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 44 Asia Pacific CRISPR and Cas genes market, by country, 2018 - 2030 (USD Million)
Table 45 Asia Pacific CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 46 Asia Pacific CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 47 Asia Pacific CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 48 China CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 49 China CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 50 China CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 51 Japan CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 52 Japan CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 53 Japan CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 54 India CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 55 India CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 56 India CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 57 Australia CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 58 Australia CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 59 Australia CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 60 Thailand CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 61 Thailand CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 62 Thailand CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 63 South Korea CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 64 South Korea CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 65 South Korea CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 66 Latin America CRISPR and Cas genes market, by country, 2018 - 2030 (USD Million)
Table 67 Latin America CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 68 Latin America CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 69 Latin America CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 70 Brazil CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 71 Brazil CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 72 Brazil CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 73 Mexico CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 74 Mexico CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 75 Mexico CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 76 Argentina CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 77 Argentina CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 78 Argentina CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 79 Middle East and Africa CRISPR and Cas genes market, by country, 2018 - 2030 (USD Million)
Table 80 Middle East and Africa CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 81 Middle East and Africa CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 82 Middle East and Africa CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 83 South Africa CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 84 South Africa CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 85 South Africa CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 86 Saudi Arabia CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 89 UAE CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 90 UAE CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 91 UAE CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
Table 92 Kuwait CRISPR and Cas genes market, by product & service, 2018 - 2030 (USD Million)
Table 93 Kuwait CRISPR and Cas genes market, by application, 2018 - 2030 (USD Million)
Table 94 Kuwait CRISPR and Cas genes market, by end-use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 CRISPR and Cas genes market segmentation
Fig. 8 Market snapshot, 2022
Fig. 9 Market trends & outlook
Fig. 10 Market driver relevance analysis (current & future impact)
Fig. 11 Market restraint relevance analysis (current & future impact)
Fig. 12 PESTEL analysis
Fig. 13 Porter’s five forces analysis
Fig. 14 Global CRISPR and Cas genes market: Product & service movement analysis
Fig. 15 Global CRISPR and Cas genes market, for product, 2018 - 2030 (USD Million)
Fig. 16 Global CRISPR and Cas genes market, for kits & enzymes, 2018 - 2030 (USD Million)
Fig. 17 Global CRISPR and Cas genes market, for vector-based Cas9, 2018 - 2030 (USD Million)
Fig. 18 Global CRISPR and Cas genes market, for DNA-free Cas9, 2018 - 2030 (USD Million)
Fig. 19 Global CRISPR and Cas genes market, for libraries, 2018 - 2030 (USD Million)
Fig. 20 Global CRISPR and Cas genes market, for design tool, 2018 - 2030 (USD Million)
Fig. 21 Global CRISPR and Cas genes market, for antibodies, 2018 - 2030 (USD Million)
Fig. 22 Global CRISPR and Cas genes market, for other products, 2018 - 2030 (USD Million)
Fig. 23 Global CRISPR and Cas genes market, for service, 2018 - 2030 (USD Million)
Fig. 24 Global CRISPR and Cas genes market, for cell line engineering, 2018 - 2030 (USD Million)
Fig. 25 Global CRISPR and Cas genes market, for gRNA design, 2018 - 2030 (USD Million)
Fig. 26 Global CRISPR and Cas genes market, for microbial gene editing, 2018 - 2030 (USD Million)
Fig. 27 Global CRISPR and Cas genes market, for DNA synthesis, 2018 - 2030 (USD Million)
Fig. 28 Global CRISPR and Cas genes market: Application movement analysis
Fig. 29 Global CRISPR and Cas genes market, for biomedical, 2018 - 2030 (USD Million)
Fig. 30 Global CRISPR and Cas genes market, for genome engineering, 2018 - 2030 (USD Million)
Fig. 31 Global CRISPR and Cas genes market, for disease model studies, 2018 - 2030 (USD Million)
Fig. 32 Global CRISPR and Cas genes market, for functional genomics, 2018 - 2030 (USD Million)
Fig. 33 Global CRISPR and Cas genes market, for epigenetics, 2018 - 2030 (USD Million)
Fig. 34 Global CRISPR and Cas genes market, for other biomedical applications, 2018 - 2030 (USD Million)
Fig. 35 Global CRISPR and Cas genes market, for agricultural, 2018 - 2030 (USD Million)
Fig. 36 Global CRISPR and Cas genes market: End-use movement analysis
Fig. 37 Global CRISPR and Cas genes market, for biotechnology & pharmaceutical companies, 2018 - 2030 (USD Million)
Fig. 38 Global CRISPR and Cas genes market, for academic & government research institutes, 2018 - 2030 (USD Million)
Fig. 39 Global CRISPR and Cas genes market, for Contract Research Organizations (CROs), 2018 - 2030 (USD Million)
Fig. 40 Regional outlook, 2022 & 2030
Fig. 41 North America CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 42 U.S. CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 43 Canada CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 44 Europe CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 45 Germany CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 46 UK CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 47 France CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 48 Italy CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 49 Spain CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 50 Denmark CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 51 Sweden CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 52 Norway CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 53 Asia Pacific CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 54 Japan CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 55 China CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 56 India CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 57 Australia CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 58 Thailand CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 59 South Korea CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 60 Latin America CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 61 Brazil CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 62 Mexico CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 63 Argentina CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 64 MEA CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 65 South Africa CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 66 Saudi Arabia CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 67 UAE CRISPR and Cas genes market, 2018 - 2030 (USD Million)
Fig. 68 Kuwait CRISPR and Cas genes market, 2018 - 2030 (USD Million)

Companies Mentioned

  • AstraZeneca plc
  • Addgene
  • Cellectis
  • CRISPR Therapeutics
  • Editas Medicine, Inc.
  • eGenesis
  • F. Hoffmann-La Roche Ltd.
  • Horizon Discovery Group plc
  • Editas Medicine, Inc.
  • GenScript
  • Danaher
  • Intellia Therapeutics, Inc.
  • Merck KGaA
  • Lonza
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • Synthego
  • Mammoth Biosciences
  • Inscripta, Inc.
  • Cibus
  • Beam Therapeutics
  • PLANTeDIT
  • Vertex Pharmaceuticals Inc.
  • Hera BioLabs
  • OriGene Technologies, Inc.
  • Recombinetics, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages160
PublishedMay 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 2.57 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.61 Billion
Compound Annual Growth Rate17.1%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

CRISPR-based Gene Editing Market Size, Share and Trends Analysis Report by Product & Service (CRISPR Kits & Reagents), Application (Biomedical, Agricultural), End-use, and Region 2024-2030 - Product Image

CRISPR-based Gene Editing Market Size, Share and Trends Analysis Report by Product & Service (CRISPR Kits & Reagents), Application (Biomedical, Agricultural), End-use, and Region 2024-2030

  • Report
  • 120 Pages
  • Global
From
CRISPR & Cas Genes Market by Component, Application, End-user - Global Forecast 2025-2030 - Product Image

CRISPR & Cas Genes Market by Component, Application, End-user - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
CRISPR Gene Editing Market by Offering, Technology, Application, End-use - Global Forecast 2025-2030 - Product Image

CRISPR Gene Editing Market by Offering, Technology, Application, End-use - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Global CRISPR Gene Editing Market Report 2024 - Product Image

Global CRISPR Gene Editing Market Report 2024

  • Report
  • 175 Pages
  • Global
From
CRISPR and Cas Gene Global Market Report 2024 - Product Image

CRISPR and Cas Gene Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.